NEW YORK--(BUSINESS WIRE)--June 19, 2006--Imagin Molecular Corporation (OTCBB:IMGM - News) announced today that Imagin Nuclear Partners (INP) a wholly owned subsidiary of Imagin Molecular Corporation has received regulatory approval to bill Medicare and Medicaid for PET imaging services. This approval allows INP to image and service patients under Medicare and Medicaid programs at its affiliate site operating at Beth Israel Medical Center on Manhattan's lower east side.

Joseph Oliverio, Chief Executive Officer stated that, "The notification of regulatory approval allows us to expand our target markets and offer our services through Beth Israel Medical Center to the more than 3,000,000 Medicare and Medicaid patients in and around New York City. This is a significant step towards mass acceptance to our business plan and methodology. We have had great success through our physician affiliates working with government and private insurers in demonstrating that PET, as a first line test, saves money with better patient care and results compared to that of traditional coronary disease detection algorithms. We expect to duplicate our cost savings and patient outcome methodology in New York City which will allow us to compete for self-insured corporations and union contracts."

About Imagin Molecular Corporation:

Imagin Molecular Corporation strategy and focus is dedicated to business opportunities in positron emission tomography (PET) manufacturing and the diagnosis of cancer, heart disease and neurological diseases. PET is an advanced medical diagnostic imaging procedure used by physicians in the detection of certain cancers, coronary disease and neurological disorders including Alzheimer's disease. Imagin Molecular Corporation has positioned the Company to be a factor in PET and ancillary molecular imaging businesses. Imagin Molecular Corporation is also the Parent of Cipher Multimedia a new Media Marketing and Distribution Solution Company that provides a Distribution Solution for publishers of digital content. Cipher Multimedia will develop marketing campaigns that will assist Imagin, Positron Corporation and other companies market their products and will continue to provide publishers a distribution solution for digital content.

About Imagin Nuclear Partners:

Imagin Nuclear Partners, a wholly owned subsidiary of Imagin Molecular Corporation, is a full-service joint venture molecular imaging partner that will own, operate and administer out-patient medical diagnostic imaging centers that utilizes PET and PET/CT scanning equipment. Imagin Nuclear Partners specializes in using evidence based bioinformatics specifically positioned in the market to provide the maximal cost effective benefit to their joint venture partner and the community.

For further information please contact Joseph Oliverio at Imagin Molecular Corporation at 630 371 5583